Abstracts tagged "Antiphospholipid syndrome and systemic lupus erythematosus (SLE)"

Abstract Number: 139 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE
Aline Kühl Torricelli¹, Michelle Remião Ugolini-Lopes ¹, Eloisa Bonfa ² and Danieli Andrade ³, ¹Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombophilia that affects young productive individuals with permanent damage and negative impact in quality of life. Recently a…
Abstract Number: 660 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE…
Abstract Number: 2635 • 2018 ACR/ARHP Annual Meeting
Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Saika Sharmeen¹, Katalin Banki² and Andras Perl³, ¹Medicine, State University of New York Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune hypercoagulable state caused by antiphospholipid antibodies (aPL) which represent a diagnostic criterion and underlie significant comorbidities in…
Abstract Number: 989 • 2013 ACR/ARHP Annual Meeting
Reproductive Counseling Program For Lupus Patients At The Systemic Lupus Erythematosus-Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery
Katherine Kim¹, Alana B. Levine², Monica C. Richey², Nadine H. Spring², Elizabeth Schulman³, Lisa R. Sammaritano², Shari E. Gelber⁴ and Jane E. Salmon², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgey, New York, NY, ⁴Obstetrics, New York Presbyterian Hospital, New York, NY
Background/Purpose: Maternal exposure to mycophenolate mofetil (MMF) during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Responding to this…
Abstract Number: 21 • 2013 ACR/ARHP Annual Meeting
Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS
Bahar Artim-Esen¹, Natalia Smoktunowicz², Charis Pericleous³, Vera M. Ripoll⁴, Ian Mackie⁵, Rachel Chambers⁶, David A. Isenberg⁷, Anisur Rahman⁸, Yiannis Ioannou⁹ and Ian Giles⁸, ¹Rayne Building, 4th Floor, Centre for Rheumatology, University College London, London, United Kingdom, ²Rayne Institute, 1st floor, Respiratory Research Unit, University College London, London, United Kingdom, ³Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Haemostasis Research Unit, 1st Floor, 51 Chenies Mews, Haemostasis Research Unit, University College London, London, United Kingdom, ⁶Center for Respiratory Research, Rayne Institute, 1st floor, University College London, London, United Kingdom, ⁷Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁸Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid antibodies have been shown to bind serine proteases (SP) involved in the coagulation cascade. Previously, we found that IgG anti-Factor(F)Xa antibody levels…
Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β₂glycoprotein I Antibodies In Systemic Autoimmune Diseases
Laura Andreoli¹, Cecilia Nalli¹, Maria-Orietta Borghi², Francesca Pregnolato³, Alessandra Zanola⁴, Claudia Grossi⁵, Maria Gerosa⁶, Flavio Allegri⁴, Michael Mahler⁷, Gary L. Norman⁷, Pier Luigi Meroni⁸ and Angela Tincani¹, ¹Rheumatology Unit, University of Brescia, Brescia, Italy, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁶Division of Rheumatology, Gaetano Pini Institute, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…
Abstract Number: 1738 • 2012 ACR/ARHP Annual Meeting
Myocardial Dysfunction and Valvulopathy Worsens with Time in Patients with Antiphospholipid Syndrome: A 10-Year Follow-up Study
MG Tektonidou¹, CF Kampolis², I. Moyssakis³, GE Tzelepis², Haralampos M. Moutsopoulos² and P. Vlachoyiannopoulos², ¹First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece, ²Department of Pathophysiology, University of Athens Medical School, Laiko Hospital, Athens, Greece, ³Department of Cardiology, Laiko Hospital, Athens, Greece
Background/Purpose: Valvular disease represents the most common cardiac manifestation among patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) positive for antiphospholipid antibodies (aPL).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].